366 related articles for article (PubMed ID: 30361677)
21. [Multimodal therapy of dyslipidemia].
Stahn A; Hanefeld M
Clin Res Cardiol Suppl; 2011 May; 6():10-6. PubMed ID: 22528173
[TBL] [Abstract][Full Text] [Related]
22. [Not Available].
Bilz S
Ther Umsch; 2017; 74(8):445-453. PubMed ID: 29461147
[No Abstract] [Full Text] [Related]
23. Proprotein Convertase Subtilisin-Kexin Type 9 (PCSK9) Inhibitors and Cardiovascular Risk: Does a Further Analysis of the Fourier Trial Suggest Changes in the Target of Lipid Lowering Therapy?
Cervelli N; Tocci G; Ferri C
High Blood Press Cardiovasc Prev; 2018 Mar; 25(1):5-7. PubMed ID: 29305812
[No Abstract] [Full Text] [Related]
24. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
Yadav K; Sharma M; Ferdinand KC
Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
[TBL] [Abstract][Full Text] [Related]
25. A Clinical Guide to Combination Lipid-Lowering Therapy.
Russell C; Sheth S; Jacoby D
Curr Atheroscler Rep; 2018 Mar; 20(4):19. PubMed ID: 29516190
[TBL] [Abstract][Full Text] [Related]
26. Dyslipidaemia and cardiorenal disease: mechanisms, therapeutic opportunities and clinical trials.
Chan DT; Irish AB; Dogra GK; Watts GF
Atherosclerosis; 2008 Feb; 196(2):823-34. PubMed ID: 17343861
[TBL] [Abstract][Full Text] [Related]
27. Controversies Regarding Lipid Management and Statin Use for Cardiovascular Risk Reduction in Patients With CKD.
Markossian T; Burge N; Ling B; Schneider J; Pacold I; Bansal V; Leehey D; Stroupe K; Chang A; Kramer H
Am J Kidney Dis; 2016 Jun; 67(6):965-77. PubMed ID: 26943983
[TBL] [Abstract][Full Text] [Related]
28. The utility of non-HDL in managing dyslipidemia of stage 5 chronic kidney disease.
Pennell P; Leclercq B; Delahunty MI; Walters BA
Clin Nephrol; 2006 Nov; 66(5):336-47. PubMed ID: 17140163
[TBL] [Abstract][Full Text] [Related]
29. Pitavastatin: novel effects on lipid parameters.
Chapman MJ
Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
[TBL] [Abstract][Full Text] [Related]
30. Potential benefit of statin therapy for dyslipidemia with chronic kidney disease: Fluvastatin Renal Evaluation Trial (FRET).
Inoue T; Ikeda H; Nakamura T; Abe S; Taguchi I; Kikuchi M; Toyoda S; Miyazono M; Kishi T; Sanai T; Node K
Intern Med; 2011; 50(12):1273-8. PubMed ID: 21673461
[TBL] [Abstract][Full Text] [Related]
31. 'Trig-onometry': non-high-density lipoprotein cholesterol as a therapeutic target in dyslipidaemia.
Jacobson TA
Int J Clin Pract; 2011 Jan; 65(1):82-101. PubMed ID: 21105969
[TBL] [Abstract][Full Text] [Related]
32. Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.
Vaziri ND; Norris KC
Blood Purif; 2013; 35(1-3):31-6. PubMed ID: 23343544
[TBL] [Abstract][Full Text] [Related]
33. Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial.
Tuttle KR; Dworkin LD; Henrich W; Greco BA; Steffes M; Tobe S; Shapiro JI; Jamerson K; Lyass A; Pencina K; Massaro JM; D'Agostino RB; Cutlip DE; Murphy TP; Cooper CJ
Clin J Am Soc Nephrol; 2016 Jul; 11(7):1180-1188. PubMed ID: 27225988
[TBL] [Abstract][Full Text] [Related]
34. LDL as a therapeutic objective.
Díaz Rodríguez Á; Mantilla Morató T
Clin Investig Arterioscler; 2019 Dec; 31 Suppl 2():1-15. PubMed ID: 31813617
[TBL] [Abstract][Full Text] [Related]
35. Poststatin Lipid Therapeutics: A Review.
Jia X; Lorenz P; Ballantyne CM
Methodist Debakey Cardiovasc J; 2019; 15(1):32-38. PubMed ID: 31049147
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease.
Toth PP; Dwyer JP; Cannon CP; Colhoun HM; Rader DJ; Upadhyay A; Louie MJ; Koren A; Letierce A; Mandel J; Banach M
Kidney Int; 2018 Jun; 93(6):1397-1408. PubMed ID: 29526502
[TBL] [Abstract][Full Text] [Related]
37. Lipid Management in Chronic Kidney Disease: Systematic Review of PCSK9 Targeting.
Zheng-Lin B; Ortiz A
Drugs; 2018 Feb; 78(2):215-229. PubMed ID: 29299849
[TBL] [Abstract][Full Text] [Related]
38. Kidney and lipids: novel potential therapeutic targets for dyslipidemia in kidney disease?
Zuzda K; Grycuk W; Małyszko J; Małyszko J
Expert Opin Ther Targets; 2022 Nov; 26(11):995-1009. PubMed ID: 36548906
[TBL] [Abstract][Full Text] [Related]
39. Using pharmacists to improve risk stratification and management of stage 3A chronic kidney disease: a feasibility study.
Chang AR; Evans M; Yule C; Bohn L; Young A; Lewis M; Graboski E; Gerdy B; Ehmann W; Brady J; Lawrence L; Antunes N; Green J; Snyder S; Kirchner HL; Grams M; Perkins R
BMC Nephrol; 2016 Nov; 17(1):168. PubMed ID: 27825313
[TBL] [Abstract][Full Text] [Related]
40. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
